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Abstract
Natural products, the greatest treasures of nature, are continous and unending source
of inspiration for mankind to haunt potentialy lead molecules for pharmaceutical
industry. The search for these natural products in medicine dates back to 1550 BC, but
the scientific period of this search is much more recent. Historically, plants were a
folkloric source of medicinal agents and as modern medicine developed, numerous
useful drugs were developed from lead compounds discovered from medicinal plants.
Today, this strategy remains an essential route to new pharmaceuticals with
multifaceted biological potential. The present investigation was undertaken to study,
in particular, the bioprospection of historically relevant medicinal plant, Cotula
anthemoides, and the value addition of its principal bioactive constituent, ursolic acid
(UA), through rational structural modifications as potential anti-cancer agents.
Cotula, the largest genus of flowering plants in Southern Hemisphere which belongs
to family Asteraceae and tribe Anthemideae. It constitutes roughly about 80 species
of plants generally known as “water buttons” or “button weeds”. Cotula anthemoides
is a well-known member of this genus commonly known as ‘Babuna’ and locally as
“Thulla bobul”. In traditional medicine, its roots were taken in Lesotho for colic and
in South Africa it is a remedy for head and chest colds. Its extensive use in the world
wide flu-epidemic of 1919 makes it an attactive target for future research. Cotula
anthemoides plant material was collected from Kelar region of District Pulwama and
its identification was assured in the Department of Plant Taxonomy, University of
Kashmir. A specimen bearing Voucher Specimen No. KASH-710 was submitted to the
same department. The aerial part of plant was dried, crushed and subjected to
extraction by various organic solvents. Bioactivity guided extraction directed us to
focus on methanolic extract. Owing to its potential cytotoxic and antimicrobial
activity, methanolic extract was further subjected to column chromatography which
resulted into the isolation of 11 individual constituents. Incisive spectral analysis
enabled us to identify unambigously four known constituents (α-pinene, coumarin,
ursolic acid, gibberlic acid A-3) and a new coumarin ester, 6-Methoxy-2-oxo-2H-
chromene-8-carboxylic acid methylester all reported for the first time from this plant.
All the isolated constituents were reevaluated against a panel of human cancer cell
lines for anticancer activity and against bacterial and fungal strains for anti-microbial
activity. It was interesting to note that, among the five compounds screened, ursolic
acid and 6-Methoxy-2-oxo-2H-chromene-8-carboxylic acid methylester exhibited
potential anti-cancer activity against four cancer cell lines, THP-1 (leukaemia), A-549
(lung), PC-3 (Prostate) and HCT-15 (colon) and significant antifungal activity against
two fungal strains, Aspergillus niger and Penicillium chrysogenum.
Taking cue from the preceeding discussion and as part of our ongoing research
program to synthsesize biocative molecules as anti-cancer agents, we aim to
undertake a research program to design and structuraly modify the UA in order to fine
tune its anti-cancer potential through click chemistry approach. Accordingly, a series
of UA- triazolyl derivatives were designed and synthesized by employing Cu (I)
catalyzed 1, 3-dipolar cycloaddition reaction of propargylated-UA derivative with
various aromatic azides. All the compounds were confimed by 1HNMR, 13C NMR, IR
and ESI-MS analysis. In 1HNMR, cyclization of azides to form triazoles, was
confirmed by resonance of H-5 of triazole ring in aromatic region as well as by the
presence of other protons in aromatic region. The structure was further supported by
the 13CNMR and DEPT, which showed all the expected carbon signals corresponding
to triazole derivatives. All the UA-triazolyl derivatives were assayed for in vitro
cytotoxicity against a panel of four human cancer cell lines including A-549 (lung),
MCF-7 (breast), HCT-116 (colon), THP-1 (leukemia) and a normal human epithelial
cell line, FR-2 using sulforhodamine-B assay. 5-fluorouracil and mitomycin-C in
addition to UA were taken as reference standards. From the anticancer screening data,
it was interesting to note that some of the compounds exhibited interresting anti-
cancer activity. Compound 9c which contains the p-bromo substitution at aryl ring
was found to be most promising compound with a 2-25 fold decrease in IC50 value.
All the UA-triazolyl derivatives were also screened for antimicrobial activity against
seven bacteria and two fungal strains. The results indicate that these compounds
displayed a broad spectrum and variable degree of antibacterial and antifungal activity
against the different tested strains. Compounds 9d, 9j and 9k were most promising
antibacterial agents and compound 9b and 9i were found to be most promising
antifungal compounds in this study.
Chapter -1
Introduction and review of literature
Introduction:
1.1. Historical persepective of medicinal plants:
Mankind has remained profoundly dependent on surrounding flora and fauna
throughout its organic evolution. Superior intellect and extraordinary
physical manoeuvrability made him to strive from the beginning to exploit
all available resources to their advantage. Plants, mostly angiosperms, which
are seed bearers readily invaded the dry land where man lived. This have
provided him all the basic amenities for the maintenance of his livelihood.
Plants directly provide man food-stuffs, fibres, shelter, raw materials for
industry, like wood, waxes, rubbers, metals etc. These also provide
ameliorants like essential oils, poisons, narcotics and above all the special
substances for the upkeep of his health i.e., medicines. To trace the
history of phytotherapy is to trace the history of humanity itself. The
discovery of the preventive,  promotive and curative properties of
certain plants must have sprung from instinct. Primitive people first used
plants as food and as a result of this desire; the link with some plant
properties would have been learnt. Medicinal plants were the main source
of products used to sustain health until the nineteenth century.
Medicinal preparations derived from natural sources, especially from
plants have been in widespread use since time immemorial. Ancient texts of
India and China contain exhaustive depictions of the use of a variety of
plant-derived medications. In fact, plants remain the main source of
medicines for a large proportion of the world’s population, particularly in
the developing world, despite the advent of the pharmaceutical chemistry
during the early twentieth century, which brought /coupled with it the
ability to synthesize an enormous variety of medicinal drug molecules
allowed mank ind treatment of previously incurable life-
threatening diseases.
Early in his history, man learnt that some plants have unusual effects on
mind and body in addition to relieving aches and pains. He considered
these plants as sacred and associated them with magic and religion. In the
course of time, he learnt the therapeutic potential which ultimately
culminated into “traditional or alternative source of medicine” and these
plants which possessed therapeutic or prophylactic properties, constitute
now what we call “the medicinal plants”. World Health Organization
(WHO) has formulated the definition for medicinal plants as those plants that
possess therapeutic properties or exert beneficial pharmacological effects on
animal / human body.
The application of plants as medicine dates back to prehistoric period. The
early civilization reveals that a considerable number of drugs used in modern
medicine have figured in ancient manuscripts such as the Rigved, The Bible,
The Holy Quran and the History of Herodotus. Over 6000 years ago, the
ancient Chinese were the first to use the natural vegetation as medicine.
Literary sources ind i ca t e the use of medicinal plants in ancient Assyria,
Egypt and China, Circa back to 3000 B.C. in the early years of common era
in Iran, Greece and Rome and during the middle ages in Arab countries,
Middle Asia, Georgia, Armenia and Europe.
India has record achievements in the field of medicine and drugs. The use
of medicinal plants as therapeutic agents can be traced in Atha rvaveda, a
religious book of Hindus, composed some 4000-5000 years ago. The
prevalent use of medicinal plants at that time can be gauged by the fact that
more than 2000 medicinal plants find special mention in this book. The
traditional but ancient Indian System of Medicine, Ayurveda, has its origin
in the days of Rig-Veda, which is one of the oldest repositories of recorded
human knowledge known to the world. Ayurvedic system of medicine was
developed into an elaborate science as is evident from the ancient Indian
medicinal literature, Charaka and Susruta Samhita, written not latter than
1000 B.C. In addition, description of medicinal plants is also available in
Brahma literature1.
1.2. Bioactivity guided fractionation of medicinal plant:
After collection and proper identification by a professional taxonomist the
plant  is subjected to drying at ambient temperature in a shady place or in an
oven with controlled airflow and temperature. The dried or stabilized plant
material is powdered and subjected to a suitable extraction process as per
standard operating procedures. The extracts are subjected to standard
chromatographic techniques of fractionation and isolation of bioactive
molecules as shown in Figure-1.
Medicinal plant
Extracts
Fractions
Pure compounds
Chemical characterization
Bioassay
Structural modification
Toxicology
Total synthesis
Figure 1.Methods for obtaining active substances from plants
This strategy is called bioactivity-guided fractionation. Bioassays can be
performed using microorganisms, molluscs, insects, cellular systems
(enzymes, receptors, etc), cell culture (animal and human), and isolated
organs or in vivo (mammals, amphibians, birds, etc) 2-3
1.3. Secondary metabolites of plant origin:
The therapeutic properties of medicinal plants are conditioned by the
presence, in their various parts, of active substances such as alkaloids,
flavonoids, glycosides, steroids, terpenoides, tannins, coumarins,
carotenoids, xanthones, iridoides and withanolides etc. As the scientific and
technological knowledge developed and various attempts to probe into the
architecture and behavior of the plant ingredients were made many
pharmacologically lead compounds were discovered. Indeed, it is the
architecture of these lead compounds whose duplication in organic
laboratories has led to the development of basic and advanced organic
chemistry. A number of medicinal plants when subjected to detailed
chemical investigation involving various separation and characterization
techniques led to isolation and identification of pure molecules which have
been pharmacologically evaluated and as a result new drugs have been
discovered, along with new applications. These bioactive molecules either
alone or in combinations are utilized as therapeutic agents or starting
material for the synthesis of drugs or  models for the synthesis of
pharmacologically active compounds or new reagents for molecular
biology research. Many of these molecules provide new and important
leads against various diseases such as cancer, AIDS, malaria, cardiovascular
disorders, typhoid and neurodegenerative diseases. Some of the important
potential lead molecules like Podophyllotoxin, Camptothecin, Taxol,
Vincristine and Vinblastine are purely anti-cancerous molecules of plant
origin. Presently there are more than 125 clinically useful drugs of known
constitution in the market which owe their existence to occurrence in
plants. Some of the representative bioactive compounds isolated from the
plant origin are shown as under.
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India has unique position in the world where traditional system of medicine
is  practiced since early times, Ayurveda being the oldest one. In addition to
Ayurveda, Siddha, Unani, homeopathy and naturopathy tibetian system of
medicine are regularly practiced for health care. These systems are plant
based. Ayurveda contributes 85% followed by homeopathy (8%), Siddha
(4%) and Unani (3.5%). Medicinal plants are utilized in traditional system of
medicine, over the counter (OTC) non prescription items
involving plant parts, extracts, galenicals and phyto-
pharmaceuticals. Phytochemical investigations of various medicinal plants
have led to the identification of quite a large number of compounds which
have been classified into few broad classes with each class having its unique
structural identity giving rise to a particular therapeutic importance. Various
classes of compounds with their pharmacological importance have been
listed as under-
1.3.1. Terpenoids:
This represents the major class, almost ubiquitous and chemically interesting
class of natural products having a carbon frame work comprised of five
carbon isoprene units. Terpenoid molecules are important for plant survival
and possess chemical and biological properties that are beneficial to humans.
They show immunomodulatory activity, inhibiting the proliferation of
activated T-cells5. These bioactive constituents exert gastric ulcer healing
activity as well as protection of the gastric mucosa. Low molecular weight
sesquiterpenes stimulate local mucus synthesis4 and prostaglandin
production, by the gastric mucosa. They also stimulate or inhibit the
phagocytosis. They are also known to have antioxidant and antiviral
activities.6-7 Most of the triterpenoid aglycones and saponins have anti-
edema activity and hypoglycemic activity which makes these compounds as
drugs of choice for the treatment of obesity and arthritis. Terpenoids from
edible legumes and soybeans show anti-cancer activity.8 Terpenoids also act
as anti-HIV-1 agents and as insect antifeedants. They are also known to
possess anti-diabetic9 and anti-neoplastic activities.10
1.3.2. Coumarins:
These are naturally occurring benzopyrones widely distributed in
umbelliferous plants.11 The pharmacological, biochemical and therapeutic
applications of simple coumarins depend upon the pattern of
substitution. Coumarins are used in perfumes, deodorants, soaps, tobacco as
flavouring agent and beverages. Coumarins can occur either free or
combined with the sugar and can exhibit  blood- thinning,9 fungicidal,12 and
antitumor activities.13 More complex compounds based on the coumarin
nucleus include the dicoumarol/warfarin anticoagulants, aflatoxins and the
psolarens (photosensitising agents). Coumarins have been used against
elephantiasis14. These have been also used as vasorelaxants15-17 and
hepatoprotective.18Some of the representative coumarins are as under-
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1.3.3. Flavonoids:
These represent a large family of low molecular weight polyphenolic
secondary metabolites that are widely spread throughout the plant kingdom,
ranging from mosses to angiosperms.19 More than 6000 different flavonoids,
including both aglycones as well as glycosides have been isolated from
plants and the number is still increasing.20 Flavonoids play important role as
defence compounds and as signalling molecules in reproduction. These
exhibit pathogenesis and symbiosis.21-
22 Flavonoids are known to have anti-inflammatory, 23 antiviral 24 and antimi
crobial 25 activities. Flavonoids have been referred to as “nature’s biological
response modifiers” due  to their inherent ability to modify the body’s
reaction to allergens, viruses and carcinogens.26Flavonoids from citrus plants
especially hesperidin, quercetin and tangeritin possess antioxidant activity27
and an ability to increase intracellular level activity of vitamin-C. Hesperidin
exerts beneficial effects on capillary permeability and blood flow.28
Flavonoids play an important role in a variety of different intercations
between plants and microorganisms, funtioning both as
defence factors (phytoalexins) and as signalling molecules.29,30 Some of the
representative flavonoids are shown as under-
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1.3.4. Lignans:
Lignans comprise a class of natural products which are cinnamic acid
derivatives and related biochemically to phenylalanine metabolism. Many
lignans like Podophyllotoxin and its derivatives are known for physiological
activity and represent drugs of choice for various kinds of cancer.
Podophyllotoxin, isolated from Podophyllum hexandrum is a lignan of
therapeutic importance well known for its antitumour activity. It acts as an
inhibitor of assembly of microtubules and arrests the cell cycle in
metaphase.31-32
1.3.5. Alkaloids:
These represent the metabolic by-products of amino acid origin and include
an enormous number of bitter, nitrogenous compounds known for their
bioactivities. Many alkaloids find applications as pharmacological
ingredients. Ergotamine has been extensively used to relieve migraine
headaches through the constriction of blood vessels. Hordenine is a potent
phenyl ethylamine alkaloid with antibacterial and antibiotic properties in
addition to its characteristic of helping in weight loss. Atropine, a tropane
alkaloid is used as a cycloplegic, to temporarily paralyze the accommodation
reflex33 and as mydriatic; to dilate the pupils. Pepaverine, an opium alkaloid
used primarily in the treatment of visceral spasm, vasospasm especially those
involving the heart and the brain, and occasionally in the treatment of
erectile dysfunction. Opium and its other deravatives find usage as potent
anaesthetics in addition to having narcotic properties.
1.3.6. Xanthones:
Biologically active plant phenols found in a few selected tropical plants.
They are beneficial in many conditions of disorders including allergies,
infections (microbial,
fungal, viral),34 high cholesterol level, inflammations, skin problems, gastroint
estinal disorders and fatigue.35 Xanthones have been found to support and
enhance the body’s immune system. These also exhibit strong antioxidant
activity more potent than vitamin C as well as vitamin E.  These are named
as super antioxidants, which are beneficial for neutralizing free radicals in
the body. Xanthones have been proved to possess beneficial effects on some
cardiovascular diseases, including ischemic heart diseases, atherosclerosis,
hypertension and thrombosis.
1.4. Natural products-need and perspectives:
The term “Natural products” covers an extremely large and diverse range of
chemical compounds derived and isolated from biological sources. These
natural products include entire organism such as plant, animal, or a
microorganism that has not been subjected to any kind of processing or
treatment other than a simple process of preservation.  These  can  be
even part of an organism such as leaves or flowers of a plant, an isolated
animal organ. These also include an extract of an organism or part of an
organism, and exudates. These can be pure compounds such as alkaloids,
coumarins, flavonoids, glycosides, lignans, steroids, sugars, terpenoids, etc.
isolated from plants, animals, or microorganisms However, in most cases
the term natural products refers to secondary metabolites, small
molecules (mol wt <2000 amu) produced by an organism that are not
necessarily for the survival of the organism.
Natural products played a prominent role in ancient traditional medicine
systems, such as Chinese, Ayurveda, and Egyptian, which are still in
common use today. According to the World Health Organization (WHO),
75% of people still rely on plant-based traditional medicines for primary
health care globally. In recent years, a significant revival of interest in
natural products as a potential source for new medicines has been observed
among academia as well as pharmaceutical companies. According to a
rough estimate 40% of the modern drugs in use have been developed from
natural products. The use of natural products with therapeutic properties is as
ancient as human civilisation and, for a long time, mineral, plant and animal
products were the main source of drugs. The industrial revolution and the
development of organic chemistry resulted in a preference for synthetic
products for pharmacological treatment. The reasons for this were that pure
compounds were easily synthesised with advent of modern techniques.
Structural modifications to produce potentially more active and safer drugs
can be easily performed and the economic power of the pharmaceutical
companies is  increasing.
However, even if we only consider the impact of the discovery of the
penicillin, obtained from micro-organisms, on the development of anti-
infection therapy, the importance of natural products is clearly enormous.
About 25% of the drugs prescribed worldwide come from plants. Of the 252
drugs considered as basic and
essential by the World Health Organization (WHO),11% are exclusively of p
lant origin and a significant number are synthetic drugs obtained from natu
ral precursor.
Interest in herbal drugs and natural medicine is undergoing a
renaissance in the present age. Plant derived products represent around
25% of the total number of clinically used drugs. It has been reported that
plants and other sources of natural products are superior sources of
molecular diversity and molecular chemotypes, particularly in the areas
where good synthetic leads do not exist. Despite competition from other
drug discovery methods, natural products are still providing their fair
share of new clinical candidates and drugs. Between 1981 and 2002, 5%
of the 1,031 new chemical entities approved as drugs by the US Food and
Drug Administration (FDA) were natural products, and another 23% were
natural product-derived molecules36as depicted below-
Figure 2.
“B”: Biological; usually a large (>45 residues) peptide or protein either isolated from an
organism/cell line or produced by biotechnological means in a surrogate host. “N”: Natural
product. “ND”: Derived from a natural product and is usually a semisynthetic modification.
“S”: Totally synthetic drug, often found by random screening/modification of an existing
agent. “S*”: Made by total synthesis, but the pharmacophore is/was from a natural
product.“V”: Vaccine. “NM”: Natural product mimic
About 25,0000  living  plant  species  contain  a much  greater  diversity  of
bioactive compounds than any chemical library made by humans.
1.5. Natural products and drug discovery:
Natural Products (NPs) traditionally have played an important role in drug
discovery and were the basis of most early medicines 37–42. Over the last 10
to 15 years advances in X-ray crystallography 43–45 and NMR 46–47 and
alternative drug discovery methods such as rational drug design 48–50 and
combinatorial chemistry 51–54 great pressure has been placed upon natural
product drug discovery programmes and during this period most major
pharmaceutical companies have terminated or considerably scaled down
their natural product based operations55–60. However, despite the promise of
these alternative drug discovery methods, there is still a shortage of lead
compounds progressing into clinical trials. This is especially the case in
therapeutic areas such as oncology, immunosuppression and metabolic
diseases where natural products have played a central role in lead discovery.
In a recent review, Newman, Cragg and Snader analysed the number of
natural product-derived drugs present in the total drug launches from 1981 to
2002 and found that natural products were a significant source of these new
drugs, especially in the oncological and antihypertensive therapeutic
areas61. In addition to providing many new drug leads, natural products and
natural product-derived drugs were well represented in the top 35 worldwide
selling ethical drugs in 2000, 2001 and 2002. 62
Natural products have been the source of most of the active ingredients of
medicines. This is widely accepted to be true when applied to drug discovery
in ‘olden times’ when more than 80% of drug substances were natural
products or inspired by a natural compound. Comparisons of the information
presented on sources of new drugs from 1981 to 2007 indicate that almost
half of the drugs approved since 1994 are based on natural products. Thirteen
natural-product- related drugs were approved from 2005 to 2007, and as
pointed out by Butler, five of these represented the first members of new
classes of drugs which include the peptides as well.
Compounds from plants, microbes and animals, as well as synthetic or semi-
synthetic compounds based on natural products cover a wide range of
therapeutic indications such as anti-cancer, anti-infective, anti-diabetic, and
show a great diversity of chemical structures. The chemical properties of
small-molecule natural products have recently been developed into drugs and
have been analysed. It is clear that, on average, natural products are more
readily absorbed than synthetic drugs. Despite these advantages and the past
successes, many large pharmaceutical companies have decreased the use of
natural products in drug discovery screening. This has been because of the
perceived disadvantages of natural products such as difficulties in access and
supply, complexities of natural product chemistry and inherent slowness of
working with natural products, and concerns about intellectual property
rights, and the hopes associated with the use of collections of compounds
prepared by combinatorial chemistry methods. Approximately 100 natural-
product-derived compounds are currently undergoing clinical trials and at
least a 100 similar projects are in preclinical development (Table.1). Most of
these compounds undergoing preclinical development are derived from leads
from plants and microbial sources. The projects based on natural products
are predominantly being studied for use in cancer or as anti-infectives, but
many other therapeutic areas are also taken care off.
Table I. Drugs based on natural products at different stages of development
Development
Stage
Plant Bacterial Fungal Animal Semi
synthetic
Total
Preclinical 46 12 7 7 27 99
Phase I 14 5 0 3 8 30
Phase II 41 4 0 10 11 66
Phase III 5 4 0 4 13 26
Pre-registration 2 0 0 0 2 4
Total 108 25 7 24 61 225
Review of literature:
1.6. Bioactive constituents from related species of Cotula anthemoides,
family-
Asteraceae:
The Asteraceae family comprises of some 23,000 plant species, the
economical and medicinal importance of which has been widely described.
An enormous variety of chemical classes have  been isolated from members
of the family, including monoterpenoids, sesquiterpenoids, sesquiterpene
lactones, diterpenes, triterpenes, coumarins, flavonoids, polyacetylenes and
benzofurans. Cotula is the largest genus of flowering plants found in the
southern Hemisphere which belongs to family Asteraceae. It includes about
80 species of plants known generally as water buttons or button weeds.
Though sufficient reports are not available on Cotula anthemoides 63 but
many species of the genus cotula have been worked out both for their
phytochemical analysis as well as bioactivity evaluation. Cotula cinerea,
commonly known as ‘Al gartoufa’, is used in Moroccan folk-medicine as an
anti-inflammatory, analgesic, antiseptic and for the treatment of
stomachache64. The extracts of this plant have been reported to show
biological activities, such as antibacterial65, analgesic66 and molluscicidal67.
Constituents such as flavonoids68, sesquiterpene lactones69 and sesquiterpene
coumarins70 have been isolated from this plant.
1.7. Brief introduction and phytochemistry of Cotula anthemoides:
Botanical description:
Family : Asteraceae
Sub-family : Asteroideae
Tribe : Anthemideae
Genus : Cotula
Species : C. anthemoides
Cotula anthemoides commonly known as ‘Babuna’ is a prostate or rising,
pale-green, hairless annual herb with several, branches arising from the base
upto 20 cm length. Leaves are nearly stalkless, ovate-oblong in shape, 1.5-5
cm (L) ×1.5-3.5 cm in dimensions and pinnately or bipinnately cut into
narrowly oblong, toothed pointed segments. Flower-heads are almost
spherical, yellow, 4-6cm across, solitary on thread like 4-5 cm long stalks.
The cup holding the flower head is saucer shaped, with phyllaries narrowly
oblong, 1-1.25×0.5-0.75 mm. Outer florets are female with an inconspicuous
corolla, about half as long as those of disc-floret corollas. Babuna is a weed
of gardens in the plains and lower altitudes in western Himalayas and is seen
to undergo flowering in March-June. It is found in open spaces and is widely
dispersed in warmer countries of the old world. The plant is weakly aromatic
resembling Anthemis cotula. As far as its usage in traditional medicine is
concerned, roots are taken in Lesotho for colic.72-73 In South Africa it is a
remedy for head and chest colds and is said to have been used extensively in
the world wide flu-epidemic of 1919. Sometimes the leaf is crushed and
snuffed into the nose.70 People living in remote areas, mostly villagers soak
this plant in hot water make a paste of it used for inflammation resulting
mostly from fractures. In addition to its use for pulmonary and stomach
troubles, it is mostly cultivated for ornamental purpose. The plant has
occasionally been used in Europe as an aromatic lawn in substitution for
Cammomile73.
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Chapter -2
Results and discussion
2. Results and discussion:
Natural products are reported to be evolutionary molecules with a profound
impact on human health.1-3 Nature’s bio-synthetic engine produces innumerate
secondary metabolites with distinct biological properties that makes them
valuable as health products or as structural templates for drug discovery.
Synthetic variation of structure and quantitative correlation of structure and
activity (QSAR) are widely used tools in drug discovery4. A common finding in
the natural product literature, in particular with regard to well established
compounds, is that the same compound is reported to act on a myriad of
targets with very different potential and with an inconsistent activity pattern,
when subjected to tempering of its structure. This motive can be conceived by
taking synthetic modification as a tool to make a particular compound to behave
differently in different situations. Discovery and development of lead compounds
from natural products has traditionally involved isolation of natural products with
biochemical activity of interest, structural elucidation by various chemical and
spectroscopic methods, development of chemical and biosynthetic methods for
producing the compound and related compounds in larger quantities, structural
modifications to produce lead structures and eventually the examination of struct
ural activity relationships (SAR) and pharma-cological properties.
Taking cue from the nature and as part of our drug discovery programme, we aim
to undertake a research programme in our institute to isolate and structurally
modify the bioactive natural products in order to fine tune their biological
potential and establish the SAR viz-a-viz structural features. In view of the
importance of natural products and their derivatives, we have collected a high
altitude medicinal plant namedCotula anthemoides which belongs to the family
Asteraceae from Kellar-Pulwama region of Kashmir valley. Identification of the
plant material was done by Department of Plant Taxonomy, University of
Kashmir and the Voucher Specimen KASH-710 has been preserved in the
Herbarium of University of Kashmir. Preliminary screening of various extracts
(Hexane, Ethyl acetate, Methanol and aqueous) for their anticancer and
antimicrobial potential confirmed only methanol extract to be significantly active
in both the assays. In case of other extracts the activity was very mild. These
results prompted us to go for the detailed phytochemical investigation of
methanol extract and hence it was chromatographed on silica gel column (60-120
mesh) with  Hexane – ethylaceate  solvent system of variable percentage
composition to yield
α-Pinene (1), coumarin (2), a new substituted coumarin ester (3), Ursolic acid (4)
andGibberlic acid-3 (5). Structural elucidation of these compounds was done by u
sing1HNMR,13CNMR, IR, MS and 2D NMR techniques.
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Keeping in view the excellent biological activity of triterpenes such as ursolic
acid, olenolic acid and betulinic acid, our work was directed towards the design
and synthesis of lead compounds from ursolic acid through robust click chemistry
approach. Accordingly a series of derivatives bearing bulky substituted triazoles
was synthesized by Cu (I) catalyzed 1, 3-dipolar cycloaddition reaction of
proparygylated ursolic acid derivative with different aromatic azides.
Click chemistry enables a modular approach to generate novel pharmacophores
utilizing a collection of reliable chemical reactions which give products
stereoselectively in high yields, produce inoffensive byproducts, are insensitive to
oxygen and water, utilize readily available starting materials and have a
thermodynamic driving force. Two types of click reactions that have influenced
drug discovery are the nucleophilic opening of strained ring systems and 1,3-
dipolar cycloadditions. Of particular interest is the copper catalyzed Huisgen
[3+2] cycloaddition between a terminal alkyne and an azide to generate
substituted 1,2,3-triazoles. This reaction is thought to proceed in a stepwise
manner starting with the generation of copper (I) acetylide (I). Density functional
theory calculations show a preference for the stepwise addition (I - II - III - IV)
over the concerted cycloaddition (I-IV) by approximately 12-15 kcal mol-1,
leading to the intriguing six membered metallocycle III.
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Postulated catalytic cycle for azide-alkyne coupling.
2.1. Characterization of compounds from Cotula anthemoides:
Compound 1: Compound 1 was obtained as transparent gummy liquid. ESI-MS
showed the molecular ion peak atm/z 159 which corresponds to molecular
formula C10H16Na, [M+Na]+; IR spectrum showed absorption bands at: 3050,
2990,2920, 1480, 1450, 1410 cm-1corresponding  to C-H stretching, C-C single
and double bond stretching respectively. Absence of absorption above 3200cm-1
confirms the absence of -OH or NH stretching. 1H-NMR data δ 5.24 (1H, s, H-
3), 2.40 (1H,  t, J = 2.20, H-1), 2.18 (2H,  t, J = 2.16, H-5), 2.00 (1H, t, J = 1.86,
H-4) 1.92 (2H, dd, J = 2.1, H-7) 1.8 (3H,  s, H-10), 1.4 (3H, s, H-8), 1.2 (3H, s,
H-9) and 13C-NMR with values at: 144.7 (C-2), 116.1 (C-3), 48.2 (C-1), 42.1 (C-
5), 38.8 (C-7), 32.2 (C-4), 32.2 (C-6), 25.2 (C-9), 22.2 (C-8), 21.0 (C-10)
confirmed the molecule as monoterpene. DEPT confirmed the presence of three
C-H, two CH2, three CH3 leaving behind the scope for two quaternary carbons.
Based on these evidences, final structure of the compound was confirmed as α-
Pinene. Comparison of its spectral data (IR, 1H-NMR, 13C-NMR and ESI-MS)
with the literature values are also in agreement.
-pinene (1)
Compound 2: Compound 2 was recrystallized from pure chloroform as shining
polyhedral crystals with melting point of 70oC. Molecular ion peak in ESI-MS at
m/z 169.2, [M+ Na]+ correspond to the molecular formula C9H6O2Na. Blue spot
on TLC when visualized under UV light and absorption bands at (nm) : 217.6,
247.3, 257.4, 318.8 nm suggested a coumarin type structural framework. IR
absorption bands at:  3040, 2955, 1690, 1620 cm-1depicted the presence of a
conjugated carbonyl in the compound; 1H-NMR spectrum confirmed the presence
of coumarin skeleton, showing two doublets one at δ 7.72 (1H, d, J = 8.0) and
second at δ 6.42 (1H,d, J = 8.0 ) for two protons of double bond in lactone ring.
Two mutiplets at δ 7.53 (2H,  m) and 7.30 (2H, m) correspond to two sets of m-
coupled protons in asymmetrically substituted benzene ring.13C-NMR values of δ
160.7, 154.0, 143.5, 131.8, 127.9, 124.4, 118.8, 116.8, 116.6 represent lactone
carbonyl oxygen attached aromatic carbons, other aromatic carbons and olefinic
carbons.13C-DEPT NMR showed the presence of three methines and three
quaternary carbons. Comparison of its spectral data with data available in
literature proved this to be coumarin with following structure.
O O
Coumarin (2)
Compound 3: Compound 3 was recrystallized from pure ethyl acetate as white
crystalline needles; melting point 119-121oC. ESI-MS of the compound showed
molecular ion peak at m/z 257.2, [M+ Na]+ which corresponds to the molecular
formula C12H10O5Na. Greenish blue spots on TLC when visualized under UV
light along with absorption bands at (nm) : 219.4, 246.2, 261.6, 325.4 suggested
the presence of coumarin nucleus in the molecule. IR absorption bands at:  3105,
1724, 1623, 1452, 1329 cm-1 represent C-H, ester carbonyl, enone carbonyl, C-O
and C-C stretch respectively; 1H-NMR spectrum confirmed the presence of
coumarin skeleton, showing two doublets at δ value of 8.15 (1H, d, J = 12 ) and
6.60 (1H, d, J = 12) for two protons of double bond in lactone ring. Two doublets
at δ value of 7.61 (1H, d, J = 2.4) and 7.39 (1H, d, J = 2.4) correspond to two m-
coupled protons in asymmetrically substituted benzene ring. Two singlets at δ
4.08 (H, s), 3.97 (3H, s) correspond to two methoxy groups.13C-NMR resonances
at δ 165.2, 162.0, 150.3, 148.0, 143.6, 125.1, 123.2, 122.8, 119.4, 108.5, 55.9,
53.4 represent lactone carbonyl, ester carbonyl, oxygen attached aromatic
carbons, other aromatic carbons and oxygen attached aliphatic carbons i.e.,
carbon atoms of methoxy groups.13C-DEPT NMR showed the presence of four
methines, six quaternary carbons and rest two carbons to be methoxy carbons.
The position of substituents in the aromatic ring was confirmed by key HMBC
connectivities. Hence, the structure of compound (3) was given as below:
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O
O O
6-Methoxy-2-oxo-2H-chromene-8-carboxylic acid methyl ester (3)
O O
O
O
H
H
O
Key HMBC connectivities of 3
Comparison of its spectral data with data available on structurally related
coumarins proved this coumarin to be new to literature.
Compound 4: Compound 4 was obtained as white crystalline powder with
melting point 283-285oC. Absorption in UV(MeOH, nm) was observed at 224.6,
235.7, and 271.8. Absorption in IR at 3438 cm-1 showed the presence of hydroxyl
group and absorption at 2930 cm-1 confirmed C-H stretch. Absorption at 1712
cm-1 and 1638  cm-1 showed the presence of carbonyl in the form of acid group
and carbon-carbon double bond stretching. Stretching frequency values of 1452
and 1382 cm-1 confirmed C-O stretching vibrations. In ESI-MS molecular ion
peak at m/z 456.5 [M+Na]+ suggested the molecular formula C30H48O3Na for
compound which in turn suggested a triterpenoid nucleus. In 1H-NMR chemical
shift, δ 5.13 (1H, s) correspond to vinylic proton at C-12, δ value of 3.49 (1H, d,
J = 12.00) corresponds to proton at C- 3 which has attached hydroxyl group.
Strong absorptions in the form of long peaks from δ 1.3-0.7 confirmed the
presence of seven methyl groups. 13C-NMR absorption peak at δ 178.4 showed
the presence of carbonyl group in the form of acid. Two singnals at δ 138.2 and δ
124.6 confirmed the presence of olefinic carbon atoms in structure. Signal at δ
76.9 showed the presence of carbon attached to oxygen i.e., C-3. Presence of acid
group was  confirmed chemically by sodium bicarbonate test. 13C-DEPT NMR
confirmed the presence of six methines, seven methyls, nine CH2 groups and
finally leaving the scope for six quaternary carbons. Comparison of spectral data
with the literature data suggested the molecule to a known cytotoxic pentacyclic
triterpenoid, ursolic acid.
HO
COOH
Ursolic acid (4)
Compound 5: Compound 5 was obtained as pale yellow powdery substance with
melting point 230-233oC. []D25 (c 0.50, MeOH) = +81.0o and UV absorption at
(MeOH, max, nm): 231.1,  245.6, 268.9. In IR spectrum absorption at (KBr, ,
cm-1):  3447 cm-1 confirmed the presence of hydroxyl group in molecule.
Presence of carbonyl in the form of acid was confirmed by absorption frequency
at 1750 cm-1and absorption at 1654 cm-1 showed the presence of carbon–carbon
double bond. Molecular ion peak at m/z 385.1 [M+K]+ confirmed by ESI-MS
suggested the molecular formula C19H22O6K for the compound. In 1H-NMR
spectrum doublet at δ 6.41 (1H, d, J = 7.6) and double boublet at δ 5.92 (1H, dd,
J = 7.6, 3.4) showed the presence of two olefinic protons located on two carbon
atoms. One singlet at δ 5.24 (1H, s) corresponds to proton on carbon atom
between methyl and carboxyl substituted carbon atoms. Chemical shift values of
4.99 (1H, d, J = 16.40) and 4.24 (1H, d, J = 2.8 ) correspond to protons on carbon
atoms substituted by carboxyl and alcohol group respectively. Absorption values
in 13C-NMR at chemical shift value of δ 183.6 and 177.8 correspond to presence
of carbonyl in the form of acid and ester respectively. Resonances at δ values of
160.8, 136.6 and 135.8 represent olefinic carbon atoms. Similarly δ values of
95.1 and 81.2 represent carbon atoms to which acid and terminal of ester groups
are attached. Absorption value of δ 73.09 represent quaternary carbon having
hydroxyl attached. Presence of acid moiety was also confirmed chemically by
sodium bicarbonate effervence test.13C-DEPT NMR confirmed the presence of
five CH2 groups, four methine groups and one methyl group thus indirectly fixing
the number of quaternary carbons to five
HO H COOH
HO
OH
Gibberlic acid-3 (5)
O
2.2. Structural modifications of ursolic acid using click chemistry
approach:
Keeping in view the available literature, concerning the biological activities of
ursolic5-12 acid and its analogues13-15 along with the availability of sufficient
amount of this compound it was convenient to go for synthetic modification and
devise and synthesize a library of its modified analogues. Ursolic acid (4) was
subjected to oxidation reaction using Jones oxidation conditions at 0 oC to result
into the formation of C-3 oxidized ursolic acid derivative (6) in almost
quantitative yield. Propargylation of the carboxylic group under Cs2CO3
condition in dry THF delivered the well poised terminal alkyne derivative of
ursolic acid (7) in excellent yield. On the other hand aromatic azides (8) were
prepared from their corresponding amines by diazotization with sodium nitrite in
acidic conditions followed by displacement with sodium azide in good to
excellent yield. 1,3-dipolar cycloaddition reaction of 7 with various aromatic
azides in presence of CuSO4.5H2O, sodium ascorbate in t-BuOH-H2O (2:1) at
45oC temperature under sonication resulted into the formation of ursolic acid
triazole derivatives (9) in excellent yield (Scheme-I). All the structures were
confimed by 1HNMR, 13C NMR, IR and ESI-MS analysis. In 1HNMR cyclization
of azides to form triazoles was confirmed by resonance of H-5 of triazole ring in
aromatic region as well as by appearance of proton signals in aromatic region.
The structure was further supported by the 13CNMR and DEPT, which showed all
the carbon signals corresponding to triazole derivatives. ESI-MS of all the
compounds for [M+Na]+was also in quite agreement.
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Scheme I. (a) CrO3, H2SO4, acetone, 0 0C, 98%; (b) Propargyl bromide, Cs2CO3, THF, rt,
92%, (c) NaNO2, H2SO4, dioxane, -10 0C, (d) aq. NaN3, -15 0C (quantitaive yield over 2-steps);
(e) Sodium ascorbate, CuSO4, t-BuOH: H2O (2:1) at 45 0 0C, 72-98 %
Using the above 1,3-dipolar cycloaddition reaction of aromatic azides (8) with (7)
in presence of CuSO4.5H2O and sodium ascorbate, a series of triazole derivatives
(9)  differing in substitution at aromatic ring were preprared in good to excellent
yield in a time span of 0.5 to 8 hours as shown in Table I.
OO
O
N
NN
R
Table I. Ursolic acid triazolyl derivatives with various substitutions.
S.No. Compound R Time(h). (min) Yield
(%)a
1 9a 08 89
2 9b 06 85
3 9c Br 05 96
4 9d CF3 02 88
5 9e Cl 08 85
6 9f
F
03 92
7 9g
I
0.5 98
8 9h
F3C
08 96
9 9i
Br
0.3 95
10 9j F 6.5 92
11 9k I 0.4 96
12 9l
CN
08 72
aYields are reported after isolation of compounds
2.3. Biology:
All the compounds including both isolated natural products and synthetically
modified analogues were assayed for their in vitro cytotoxic activity againsta
panel four different human cancer cell lines and anti-microbial activity against a
set of seven bacterial and two fungal strains respectively.
2.3.1. Cytotoxic activity:
The cytotoxic activity of methanolic extract and isolated constituents thereof was
studied against a panel of human cancer cell lines including THP-1 (leukaemia),
A-549 (lung), PC-3 (Prostate) and HCT-15 (colon) by using sulphorhodamine-B
assay.
Methanolic extract was found to be potentially active against all the tested cancer
cell lines and it showed concentration dependent percentage growth inhibition
with excellent activity at higher dose concentrations. These results are shown in
Figure 1 and were made the base for further detailed investigations.
Figure 1: In vitro cytotoxic activity of the methanolic extract of Cotula anthemoides at
different concentrations.
In case of the isolated constituents the cell lines were subjected to constant
concentration of 50 µg/ml for 48 hours and percentage of dead cells was
evaluated. The percentage of the dead cells in case of THP-1 (leukaemia), A-549
(lung), PC-3 (Prostate) and HCT-15 (colon) was found to be highest for
compounds (3) and (4). In order to evaluate the cytotoxic potential of unknown
isolated coumarin methylester (3) in detail, different concentrations of this
compound in the range of 10, 20, 40, 60, 80, 100 µg/ml were analysed against
same cancer cell lines and it was found that compound (3) exhibited a dose-
dependent inhibitory effect on all cell lines tested in the 10-100 µg/ml dilution
range (Figure-2 & Table II).
Figure 2: In vitro cytotoxic activity of new coumarin ester from Cotula anthemoides at
different
concentrations.
TableII. In-vitro cytotoxic activity of compound 1-5.
Tissue Type Leukemia Prostate Colon Lung
Cell line Type THP-1 PC-3 HCT-15 A549
Comp. Conc.
(µg/ml)
% Growth inhibition
1 50 26 35 28 43
2 50 63 58 51 40
3 10, 20, 40, 60, 28, 39, 52, 66, 73, 13, 24, 45, 58, 16, 24, 31, 37, 24, 38,47,
5-FU = 5-flourouracil, Mito-C = Mitomycin-C
The IC50 values were found to be 40µg/ml (THP-1), 43 µg/ml (A-549), 76 µg/ml
(HCT-15) and 47 µg/ml (PC- 3). Of the four cell lines that were tested, THP-1
(leukemia) and A-549 (lung) malignant cell lines were found to be the most
susceptible.
Encouraged by the potential cytotoxic activity of compound (3) and (4) and with t
he good abundance of compound (4) in hand, we shifted our attention towards its
structural modifications. As a result, a battery of its triazolyl analogues were
prepared and evaluated for anticancer activity against a panel of human cancer
cell lines- A-549, THP-1, MCF-7, HCT-116 along with a normal cell line, FR-2
and the results are reported in Table III. Initially all the compounds were
screened at 50μM concentration. All those derivatives which depicted significant
activity at this very particular concentration were further screened at different
lower concentrations for evaluation of their respective IC50 values (Table IV).
From the percentage growth inhibition data and IC50 values (Tables III & IV) it is
concluded that:
(a) Compounds 4, 7, 9a, 9c, 9g and 9l were found to be the most promising
against all the tested cell lines. Results confirm the synthetically modified
compounds to be better in activity than the parent ursolic acid (4)
(b) Among all the promising compounds, compounds 9a, 9c and 9g were the
most active  in this study. Compound 9c which contains the p- bromo substitution
at aryl ring was found to be most promising with IC50 values in the range of 1-18
μM. It was observed from the data that this compound was specifically active
against two cancer cell lines, THP-1 and HCT-116 with IC50 values of 1.0 and 1.9
respectively.
(c). From IC50 values, it is clear that almost all the active compounds exhibit less
cytotoxic activity towards the normal epithelial cell line, FR-2 compared to their
potential against cancer cell lines
80, 100 81 68, 73 55, 59 68, 78, 86
4 50 86 91 77 79
5 50 43 39 35 24
5-FU 1x10-5M 32 45 78 48
Mito-C 1x10-5M 23 69 31 51
Table III. In-vitro cytotoxic activity of synthetically modified compounds.
Tissue Lung Breast Colon Leukemia Normal
cell line
Cell Line A-549 MCF-7 HCT-116 THP-1 FR-2
S. No Code Conc.(µM)
01 4 50 61 57 53 84 66
10 28 36 55 31 31
02 7 50 78 42 96 88 86
10 50 22 74 42 33
03 9a 50 64 51 78 83 45
10 43 28 44 54 12
9b 50 27 40 02 47 NDa
04 9c 50 63 78 92 95 93
10 45 44 80 74 85
05 9d 50 30 03 16 27 ND
9e 50 26 52 49 09 ND
06 9f 50 18 15 12 49 ND
9g 50 67 76 78 79 ND
07 10 43 54 44 56
08 9h 50 46 04 23 73 ND
09 9i 50 16 03 10 32 ND
10 9j 50 03 04 03 02 ND
11 9k 50 01 08 08 01 ND
12 9l 50 26 34 67 55 46
13 10 13 17 44 32 14
14 5-FUb 20 86 NT 76 96 ND
15 Mito-Cc 01 70 82 NT NT ND
a =Not determined,b = 5-flourouracil, c = Mitomycin-C
Table IV. IC50 of potential candidates.
Tissue Type Lung Leukemia Colon Breast
Cell Line Type A-549 THP-1 HCT-116 MCF-7
S.No. Code IC50 Values in (µM)
1 4 33 9.1 42 37
2 7 15 13 2.3 56
3 9a 24 11 14 39
4 9c 18 1.0 1.7 15
5 9g 19 9.4 15 13
6 9l >100 37 19 79
2.3.2. Antibacterial activities.
Antimicrobial activity of all compounds was evaluated against a set of seven
bacterial strains (including both Gram-positive and Gram-negative) and two
fungal strains and their potency was assessed by measuring the inhibition zones,
MIC and MBC/MFC values. The results (MICs and MBC/MFC) indicate that
chemical constituents displayed a broad spectrum and variable degree of
antibacterial activity against the different tested strains. The most susceptible
bacterial strain incase of known and new constituents (Table V) was found to be
Staphylococcus aureus (MIC=64µg/ml, MBC >64 µg/ml) and Bacillus subtillis (
MIC=64µg/ml, MBC >128 µg/ml) respectively. Concerning the Gram negative b
acteria, isolates demonstrated a significant activity especially against Shigella
dyssenteriae (MIC=64 µg/ml). Some Gram-positive bacterial strains exhibited
lower MIC/MBC values than Gram-negative bacteria thereby indicating that
isolates are more active against Gram-positive bacteria as compared to Gram-
negative bacteria.
Table V. Antibacterial activities of compounds 1-5.
Co
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Diameter of inhibition zone (mm)
1 24.3 16.6 21.5 22.6 19.6 19.1 15.6 >64, >128, >64,
>32, 128, >128,
>128
>128, 256,
>128, >64,
>128, 256, 256
2 19.0 17.5 19.9 17.3 16.6 20.0 14.8 128, >128, 128,
256, >256, >128,
>256
256, >256, 256,
>256, 512,  256,
>512
3 26.1 19.6 23.3 25.1 18.3 22.2 17.9 >64, >128, 128,
128, >128, 128,
>128
>128, 256, >128
, >128, 256,
>128, 256
4 23.7 22.8 21.7 25.6 20.7 23.3 18.3 >64, 128, 128, 64,
128, 64, >128
128, >128, >128
, >64, >128, >64
,  >128
5 18.3 20.7 19.7 15.9 17.6 19.3 16.2 >128, 128, >128,
256, >128, 128, 256
256, >128, 256,
>256, 256,  256,
>256
AMP 36.6 38.0 34.9 37.6 33.7 39.6 39.5 8, >4, >8, >4, >8, 4,
4
16, 8, >16, 8,
16, >4 >4
VAN 34.5 36.2 33.6 37.8 32.1 38.9 36.6 >8, 8, >8, >4, 16,
>4, 8
16, 16, >16, 8,
>16, 8, >8
AMP = Ampicillin (5µg disc)  andVAN = Vancomycin
The two fungal strains viz., Penicillium chrysogenum and Aspergillus niger were
also susceptible to isolated constituents showing MIC/MFC = 8 µg/ml 16 µg/ml
respectively (Table VI).
Table VI. Antifungal activities of compounds 1-5.
Compound P. chrysogenum A.niger MIC MFC
Zone of inhibition (mm)
1 07.40 11.60 64, 32 128 , >32
2 80.20 09.90 >64, >64 >128, 128
3 09.15 10.65 >32, >32 128, 64
4 12.24 14.34 >8, 8 >16, 16
In case of synthetically modified compounds the results of antimicrobial activity
(Table VII & VIII) were very interesting-
(a) Increase in hydrophobicity in case of 9a and 9b resulted in increase of
antibacterial potential compared to parent compound (4) but this
increase was very low.
(b) Significant increase in antibacterial activity in case of compounds 9d,
9f, 9g, 9h, 9j, 9k and antifungal activity in case of compounds (7),
9b, 9i, and 9l can be accessed from their respective MIC and
MBC/MFC values. All these compounds which showed enhanced
activity contain hetero atoms fluorine and iodine at aryl ring site
except compound 9b.
(c) Compounds 9d, 9j and 9k were most potent antibacterial analogues
out of the whole series with enhanced activity compared to parent
compound (4).
(d) Tremendous increase in antifungal activity was seen in case of
compounds 9b and 9i.
Table: VII.Antibacterial activities of synthetically modified compounds.
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Zone of inhibition(mm)
4 23.70 22.80 21.70 25.62 21.75 23.35 18.38 >64,128, 128,
64, 128, 64,
>128
128,>128,
>128,>64, >128,
>64, >128
5 06.85 08.22 128, 64 256, 128
Fluconazole 13.20 19.60 >4, 4 8, >4
7 17.45 16.20 17.75 19.25 15.90 15.40 13.85 >128,>128,
128, >64,256,
256, >256
256,>256,>128,
128, >256,256,
512
9a 22.60 23.55 16.30 21.70 12.65 12.00 10.50 >64, >64,>12
8, 128,
256,>128,
256
>128, >128,
256, 128, >256,
>256, >512
9b 25.35 24.90 15.45 26.95 10.70 11.80 09.00 64, >64, 256,
64, >256,
256, 512
>64, 128, >256,
>64, >512,
512,>512
9c 18.85 15.60 19.30 21.80 19.00 21.55 16.90 128,>128,
128, 64,
>128, 128,
>256
>128,>256, >1
28,128, 256,>1
28 ,256
9d 31.45 33.20 31.15 33.40 27.25 32.60 25.45 >16, 16,
16,>8, 32, 16,
32
>32, 32, 32, 16,
>32, >16, 64
9e 17.80 19.35 17.00 17.80 14.00 16.65 13.00 >128,128,128
, 128,>256,25
6, >256
>256,>128, >1
28,128, 512,25
6,512
9f 25.50 27.35 27.00 31.45 25.90 29.75 22.60 >32, 64, >64,
>16, >32, 32,
>32
64, >64, 128,
>32, >64, >32,
>64
9g 26.40 29.00 25.55 33.00 28.70 31.00 27.65 32, >32, >64,
16, 32, 32,
>16
64, 64, 128, 32,
64, >32, 32
9h 24.75 30.25 28.70 26.50 30.15 27.70 23.90 >32, 32,
64,>16, 32,
>32,32
64, >32, >64,
>32,>32,64, >32
9i 14.95 15.55 12.00 16.45 11.50 12.90 08.40 256, 256,
>256,>128,
256, 256, 512
>256, >256,
512, >256, 512,
>256, >512
9j 34.80 31.45 33.15 35.70 32.10 34.15 27.65 8, >16, 16, 8,
16, >4, >16
16, >32, 32, >8,
>16, 8,>32
9k 32.65 30.00 29.00 34.20 31.00 25.95 28.60 16, >16, 32,
8, 16, >16, 16
>16, >32, 64,
16, >16, >32,
32.
9l 15.50 15.65 12.60 16.70 08.70 09.00 11.45 >256, 256,
256,>128,
>256,512,
>256
512, >256, 512,
>256, 512,
>512, 512
Table: VIII. Antifungal activities of synthetically modified compounds.
Compound
P.
chrysogenum
A.niger MIC MBC
Zone of inhibition (mm)
4 12.30 14.34 >8,8 >16, 16
7 16.50 21.75 4, >4 >8, 8
9a 17.20 15.70 4, >8 >8, 16
9b 19.80 20.35 4, 4 8, >4
9c 14.60 17.78 8, >8 >16, >16
9d 10.50 09.10 16, >16 >32, 64
9e 12.00 11.70 8, >8 16, >16
9f 09.85 12.65 32, >16 64, >32
9g 10.10 14.20 >32, >8 64, 16
9h 14.40 12.75 8, >8 16, 32
9i 20.40 22.90 4, 4 8, >4
9j 09.00 15.60 >32, >8 64, >16
9k 10.80 10.25 >16, >32 32, >64
9l 16.90 19.30 >4, 4 >8, 8
Fluconazole 13.20 19.62 >4, 4 8, >4
Conclusion:
To sum up a bioassay guided fractionation protocol for methanolic extract of
Cotula anthemoides resulted in the isolation of one new and four known chemical
constituents, all reported for the first time from this plant. The chemical
constituents were characterized by making use of various spectroscopic
techniques like 1HNMR,13CNMR, HMBC, IR and ESI-MS . All these
compounds were assayed for their cytotoxic and antimicrobial potential against a
panel of human cancer cell lines and various bacterial and fungal strains.
Compounds 3 and 4 were found to be significantly active in both the tested
assays. On the basis of potential biological activity of compound 4 along with its
good quantity in hand, it was further subjected to structural modifications to alter
its biological potential. As a result, a series of ursolic acid-triazolyl derivatives
were synthesized by click chemistry approach. All the derivatives were screened
for their anticancer and antimicrobial activity. Anticancer activity was tested
against a panel of four human cancer cell lines including A-549, THP-1, MCF-7,
HCT-116 along with a normal epithelial cell line, FR-2. Antimicrobial activity
was evaluated against seven bacteria and two fungal strains. From the anticancer
screening data, it was interesting to note that some of the compounds exhibited
interresting anti-cancer activity. Compound 9c which contains the p-bromo
substitution at aryl ring was found to be most promising with a 2-25 fold decrease
in its IC50 value. The results of antimicrobial screening (MICs and MBC/MFC)
indicate that these synthesised compounds displayed a broad spectrum and
variable degree of antibacterial and antifungal activity against the different tested
strains. Compounds 9d, 9j and 9k were most promising antibacterial analogues
and compounds 9b and 9i were found to be most promising antifungal analogues
in this study.
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Chapter -3
Experimental
3.1 General:
Melting points were determined on digital Buchi B-545 melting point apparatus
using glass capillaries and are uncorrected. Infrared spectra were recorded as cm-
1absorption using KBr pellet method on Perkin Elmer-FT-IR spectrometer.
Optical rotations were measured in Jasco DIP-360 digital polarimeter. Ultraviolet
(UV) spectra’s were recorded in methanol on Specard S 100. 1H NMR and 13C
NMR, COSY, HMBC, HSQC were recorded on 500, 400 and 100 MHz Bruker
Daltonics spectrometers. The chemical shifts (δ) are reported in ppm relative to
tetramethylsilane (TMS) as internal standard and coupling constants were
measured in Hz. Mass spectra were recorded on Bruker Daltonics electro spray
ionization apparatus.
Column chromatography was carried out on silica gel (Qualigens, 60-120 mesh)
in a glass column with diameter 7.0 cm and length 90 cm. Pre-coated silica gel
thin layer chromatographic (TLC) plates were viewed with ultraviolet light at 254
nm for
fluorescence quenching spots and at 366 nm for fluorescent spots. Cerric sulphate
, sulphuric acid, anisaldehyde, vanillin and FeCl3 were used as spraying reagents
to visualize different spots.
3.2 Plant material:
The aerial parts of plant Cotula anthemoides were collected from the hilly area of
Kellar- Pulwama in the month of May 2011 and after proper identification by Dr.
A. R. Naqshi (Professor of Plant Taxonomy, University of Kashmir) a Voucher
Specimen KASH-710 was submitted to the same department for records.
3.3 Extraction and isolation:
Shade dried and coarsely powdered aerial parts of plant material (1.5kg) were
subjected to defatting with petroleum ether for 48×3 hours at room temperature.
Defatted plant material was dried further and extracted with methanol for 48×3
hours at room temperature. Evaporation of the solvent under reduced pressure
delivered 65 gm of methanolic extract. This extract was dissolved in minimum
amount of methanol, mixed with silica gel with mesh-size 60-120 and processed
to result in fine and granular slurry. The dried slurry was loaded on a glass
column of diameter 7.0 cm and length 90 cm and column chromatographed on
silica gel with hexane, ethylacetate and methanol solvent systems of variable
composition (Pure hexane, 5, 10, 15 % hexane - ethyl acetate etc.). Column
elution resulted in collection of following fractions (100ml each): 1-75 (pure
hexane, fraction-A), 75-170 (hexane – ethylacetate 95:05, fraction B) 170-310
(hexane - ethyl acetate 90:10, fraction-C), 310-400 (hexane - ethylacetate 85:15,
fraction-D) 400-475 (hexane - ethyl-acetate 80:20, fraction-E) 475-600 (hexane -
ethylacetate 75:25, fraction F) 600-710 (hexane - ethylacetate 65:35, fraction-G)
710-850 (hexane - ethylacetate 55:45, fraction-H) 850-1000 (hexane - ethyl-
acetate 45:55, fraction-I) 1000-1150 (ethyl-acetate - methanol95:05, fraction-J)
1150-1310 (ethylacetate - methanol 90:10, fraction-K) 1310-1400 (ethylacetate -
methanol 80:20, fraction-L) 1400-1550 (ethyl-acetate - methanol 60:40, fraction-
M) 1550-onwards (pure methanol, fraction N).
Fraction B on concentration under reduced pressure resulted in compound 1
which was obtained as pungent smelling transparent gum like mass and was
purified by filtration through a silica gel patch. Fraction-C on evaporation and
recrystallization from ethylacetate afforded compound 2. Fraction-D upon
concentration under reduced pressure resulted in precipitation of compound 3
which was also present in fraction- C but in very low concentration. Fraction F
and G resulted in separation of compound 4 as yellowish impure powder. It was
subjected to continued solvent treatment (hexane: chloroform, 97:03) for
purification and white fine granular powder was obtained which gave a single
pinkish spot on TLC when charred with ceric sulphate. Compound 5 got
precipitated as yellowish powder from fraction-L on evaporation under reduced
pressure and finally it was recrystallized from Isobutanol and water (95:05) after
96 hours.
Compound 1:Transparent gummy liquid, Rf = 0.52 (CHCl3 - Hexane, 70:30 v/v),
[]D25 (c 0.25, MeOH): -37 ; UV (MeOH, max, nm): 216, 229.2; IR (KBr, , cm-
1): 3050, 2990, 2920, 1480, 1450 1410; ESI-MS: m/z 159.02
[M+Na]+, (calculated for C10H16Na); 1H-NMR (400 MHz, CDCl3, δ, ppm, J/Hz):
5.24 (1H, s, H-3), 2.40 (1H,  t, J = 2.20, H-1), 2.18 (2H,  t, J = 2.16, H-5), 2.00
(1H, t, J = 1.86, H-4), 1.92 (2H, dd, J = 2.1, H-7), 1.8 (3H,  s, H-10), 1.4 (3H, s,
H-8), 1.2 (3H,  s,  H-9); 13C-NMR (100 MHz, CDCl3, δ, ppm): 144.7 (C-2), 116.1
(C-3), 48.2 (C-1), 42.1 (C-5), 38.8 (C-7),  32.2 (C-4), 32.2 (C-6),  25.2 (C-9),
22.2 (C-8), 21.0 (C-10).
Compound 2: Transparent crystalline compound, recrystallized from chloroform
; melting point 70oC; Rf : 0.40 (CHCl3- Hexane, 1:1 v/v);  IR (KBr, , cm-1):
3040, 2955, 1690, 1620, 1480; ESI-MS: m/z, 169.2 [M+Na]+, (calculated for
C9H6O2Na); 1H-NMR (400 MHz, CDCl3, δ, ppm, J/Hz): 7.72 (1H, d, J = 8.0),
7.61 (1H,  d, J = 2.4), 7.53 (2H,  m), 7.30 (2H, m), 6.42 (1H, d, J = 8.0 ); 13C-
NMR (100 MHz, CDCl3, δ, ppm): 160.7, 154.0, 143.5, 131.8, 127.9, 124.4,
118.8, 116.8, 116.6.
Compound 3: Fine white crystalline substance, recrystallized from pure
ethylacetate; melting point 119-121oC; Rf :  0.48 (CHCl3 - Hexane, 1:1 v/v);
[]D25 (c 0.40, MeOH): -59o; UV (MeOH, max, nm): 236.4,  246.2, 261.6; IR
(KBr, , cm-1):  3105, 3017, 2970, 1724, 1623, 1452, 1329; ESI-MS: m/z, 257.20
[M+Na]+, (calculated for C12H10O5Na); 1H-NMR (400 MHz, CDCl3, δ, ppm,
J/Hz): 8.15 (2H,  m), 7.61 (1H,  d, J = 2.4), 7.39 (1H,  d, J = 12.0), 4.08 (3H, s),
3.97 (3H, s); 13C-NMR (100 MHz, CDCl3, δ, ppm): 165.2, 161.9, 150.3, 147.9,
143.6, 125.1, 123.2, 122.8, 119.4, 108.5, 55.8, 53.4.
Compound 4:White crystalline powder ; melting point 283-285 oC; Rf:  0.62
(Hexane - EtOAc, 1:1 v/v); []D25 (c 0.30, MeOH) = +59o; UV (MeOH, max,
nm): 244.60,  255.72, 271.80; IR (KBr, , cm-1):  3438, 3403, 2930, 1689, 1658,
1452, 1382, 1242, 1040; ESI-MS: m/z, 456.50 [M+Na]+, (calculated for
C30H48O3Na); 1H-NMR (400 MHz, CDCl3, δ, ppm, J/Hz) : 5.13  (1H,  s), 3.49
(1H,  d, J = 12.0), 3.01 (1H,  s), 2.51 (1H, s), 2.10 (1H, d, J = 8.0), 1.86 (3H,
m), 1.41 (12H,  m), 0.84 (21H,  m); 13C-NMR (100 MHz, CDCl3, δ, ppm): 178.4,
138.2, 124.6, 76.9, 54.8, 52.4, 47.1, 46.9, 41.7, 39.9, 39.76, 39.7, 39.6, 39.4, 39.3,
39.1, 39.1, 38.9, 38.5, 38.4, 36.5, 28.3, 23.3, 21.1, 17.1, 16.9, 16.1, 15.3.
Compound 5: Pale-yellow powdery substance; melting point 230-233 oC;
Rf : 0.55 (MeOH - EtOAc, 3:7v/v); []D25 (c 0.50, MeOH) = +81.0o; UV (MeOH,
max, nm): 231.12,  245.66, 268.90; IR (KBr, , cm-1):  3447, 3373, 2969, 2934,
2877, 1750, 1654, 1483,1448, 1329, 1263, 1171; ESI-MS: m/z, 385.10 [M+K]+,
(calculated for C19H22O6K); 1H-NMR (400 MHz, CDCl3, δ, ppm, J/Hz) : 6.12
(1H,  d, J = 7.6), 5.72 (1H,  dd, J = 7.6, 7.6), 5.08 (1H,  s), 4.80 (1H, d, J = 16.4
), 3.86 (1H, d, J = 2.8 ),3.18  (1H,  t, J = 1.2 ), 3.08 (1H, d, J = 8.8 ), 2.54 (1H, d,
J = 8.4), 2.22 (1H, d, J = 12.40), 2.10 (1H, d, J = 12.40), 1.85(2H, m) 1.72 (2H,
dd, J = 10, 8.8) 1.65 (2H, d, J = 8.4) 1.60 (2H, m) 1.22 (3H, s); 13C-NMR (100
MHz, CDCl3, δ, ppm): 183.6, 177.8, 160.8, 136.6, 135.8,  110.1, 95.06, 81.1,
73.1, 57.5, 56.5, 54.9, 54.7, 53.80, 48.1, 46.7, 42.3, 20.5, 17.5.
3.4. Experimental:
3.4.1. Synthesis of compound 6:
To a solution of ursolic acid (400 mg, 0.88 mmol) in acetone (9 ml) at 0oC, two
drops of Jones reagent was added and reaction mixture was stirred at room
temperature. Reaction was monitored by TLC (3:7, ethylacetate - hexane) till its
completion in around 2 hours. Water was added to the reaction mixture and
extraction was done by ethylacetate. The product was purified by column
chromatography to deliver the pure compound 6 (365 mg, 91% yield).
O
COOH
White solid; mp: 276oC
1HNMR(400MHz,CDCl3, ): 5.29 (1H, s), 3.20 (1H, d, J = 12 Hz), 2.28 (2H, t
, J = 4.2 H z), 2.14 (2H, d, J = 2.8 Hz), 1.90 (3
H, t, J = 6 Hz), 1.81 (H
, m ), 1.76 (1H, m), 1.56 (3H, s), 1.50 (6H, s), 1
.48 (3H, s ), 1.35 (3H, s), 1.10 (6H, s).
13CNMR (100MHz, CDCl3, ): 216.6, 181.5, 151.9, 123.2, 53.6, 52.2, 47.8, 46.
8, 41.7, 39. 9, 39.8, 39.7, 39.6, 39.4, 39.3, 39.1, 39.1, 38.9, 38.5, 38.4, 36.6, 28.3,
23.3, 21.2, 17.1, 17.0, 16.1, 15.3.
IR (KBr): 2930, 1718, 1657, 1456, 1378, 1242, 1042, 751.0
cm-1
Mass (ESI-MS): 455.46 [M+Na]+
3.4.2. Synthesis of compound 7:
To a solution of 6 (365 mg, 0.8 mmol) in THF was added cesium carbonate (521
mg, 1.6 mmol) and propargyl bromide (476 mg, 4 mmol) and the reaction
mixture was stirred at room temperature for about 4 hours. Reaction was
monitored by TLC (EtoAc- Hexane, 3:7 v/v) and the crude product was
subjected to column chromatography to give pure compound 7 (356 mg, 98%
yield).
O
O
O
White powdery solid; mp: 279 oC
1HNMR (400 MHz, CDCl3, ): 5.30 (1H, m), 4.62 (2H, dd, J = 12, 12 Hz), 2.59 (1H,
s), 2.54 (1H , m), 2.40 (2H, t, J = 4.2 Hz), 2.14 (2H, d, J = 2.8 Hz), 1.90 (3H, t, J = 6 Hz),
1.81 ( 1H, m ), 1.76 (1H, m), 1.56 (3H, s), 1.50 (6H, s), 1.48 (3H, s), 1.35 (3H, s), 1.10 (6H,
s).
13C NMR (100 MHz, CDCl3, ): 217.9, 176.6, 137.9, 125.6, 78.1, 74.4, 55.3, 52.9,
51.6, 48.2, 47.4, 46.8, 42.2, 39.6, 39.3, 39.1, 38.8, 36.7, 36.4, 34.2, 26.6, 23.5, 23.4, 21.5,
21.1, 17.2, 17.0,  15.3.
IR (KBr): 2939, 2565, 2455, 2417, 1717, 1654, 1464,
1378, 1246, 1042, 779, 718 cm- 1
Mass (ESI-MS): 516.36 [M+Na]+
3.4.3. General procedure for the synthesis of 8:
To a solution of aromatic amine (1 equivalent) in 1, 4- dioxane at -15 0C, 5
equivalents of 2M Sulphuric acid was added in small installments while stirring.
After 5 minutes 2 equivalents of 3M sodium nitrite solution was added drop wise
and after 30 minutes 3 equivalents of 3M sodium azide solution was added
carefully. Reaction mixture was brought to room temperature and extracted with
diethyl ether. Organic layers were washed with saturated sodium bicarbonate
solution and dried over anhydrous sodium sulphate and evaporation was done at
reduced pressure at room temperature to deliver the pure azides in quantitative
yield which were used for further reaction without purification.
3.4.4. General procedure for the synthesis of compounds 9a-9l:
To a solution of compound 7 (15 mg, 0.03 mmol) in tBuOH - H2O (2:1, 5 ml)
was added sodium ascorbate (1.2 mg, 0.006 mmol) and CuSO4 (1.2 mg, 0.0045
mmol). To this mixture, aryl azide (2 equivalents) was added and the reaction
mixture was sonicated at 45 oC till its completion was monitored by TLC. After
the reaction was completed, it was diluted with water and extracted with
ethylacetate (2×20 ml). Organic layer was dried over sodium sulphate and
purified through column chromatography to give pure 9a-9l in 72-98 % yield.
Compound 9a:
OO
O
N
NN
Yellowish gummy liquid:
1HNMR (400MHz, CDCl3, ): 8.03 ( 1H, s), 7.73 ( 2H, t, J = 8.5 Hz),7.53 (2H, t, J =
15.5 Hz), 7.44 ( 1H, t, J = 15.5), 5.25 (3H, m), 2.48 (1H, m), 2.31 (3H, m), 1.87 ( 2H, m ),
1.60 (3H, m), 1.50 (3H, s), 1.44 (6H, s), 1.38 (3H, s), 1.20 (3H, s), 0.53 (3H, s).
13C NMR (100 MHz, CDCl3, ):    217.8, 177.5, 14.7, 138.0, 136.9, 129.7, 128.8,  125.4,
122.4, 120.4, 77.2, 77.0, 76.7, 57.2, 52.9, 48.2, 47.3, 46.6, 39.2, 39.1, 38.8, 36.6, 36.6, 34.1,
29.7, 26.6, 23.3,  23.3, 21.4, 21.1, 19.5, 16.9, 16.7, 15.1.
IR (KBr): 2926, 2858, 1707, 1697, 1455 cm-1
Mass (ESI-MS): 633.42[M+Na]+
Compound 9b:
O
O
O
N
NN
White solid; mp: 285 oC
1HNMR (400 MHz, CDCl3, ): 8.03 (1H, t, J = 8 Hz), 7.97 (2H, t, J = 8 Hz), 7.66
(2H, d, J = 8 Hz), 7.57 (3H, m), 5.42 (3H, m), 2.50 (1H, m), 2.34 (1H, m), 2.01 (1H, t, J =
4 Hz), 1.81 (3H, m ), 1.74 (3H,  m), 1.54 (3H, s), 1.03 (3H, s), 0.97 (3H, s), 0.93 (3H, s),
0.89 (3H, s), 0.86 (3H, s), 0.64 (3H, s).
13C NMR (100 MHz, CDCl3,): 217.7, 177.6, 143.2, 138.2, 134.2, 133.6, 130.5,
128.4, 127.9, 127.1, 126.6, 125.5, 124.9, 123.4, 122.4, 77.3, 55.2, 52.9, 48.3, 47.3, 46.7,
42.2, 39.5, 39.3, 39.13, 38.83, 36.70, 36.6, 34, 32.5, 26.6, 23.4, 23.4, 21.5, 21.1, 19.6, 17.1,
17.0,  15.1.
IR (KBr): 2919, 2850,1709, 1692, 1542,1449, 1383 cm-1
Mass (ESI-MS): 684.24 [M+Na]+
Compound 9c:
O
O
O
N
NN
Br
White papery solid; mp:279 oC
1HNMR (400MHz,CDCl3, ): 8.08 (1H, s), 7.72 (4H, dd, J = 8, 8 Hz), 5.31
(3H, m), 2.50 (1H,
m), 2.59 (1H, m), 2.43 (1H, m), 2.33 (1H, d, J = 12
Hz), 2.07 (2 H, m ), 1.95 (3H, m), 1.35 (3H, s), 1.13
(3H, s), 1.04 (3H, s), 1.0 (3H, s), 0.99 (3H, s),
0.93 (3H, s), 0.61 (3H, s).
13C NMR (100 MHz, CDCl3, ): 216.6, 176.5, 143.0, 137.1, 134.9, 131.9,
124.5, 121.5, 121.3, 120.8, 56.1, 54.2, 52.0, 47.2,
46.3, 45.7, 41.2, 38.5, 38.1, 37.8, 35.6, 33.1, 31.5,
25.6, 23.1, 22.4, 22.3, 20.4, 20.1, 16.0, 15.8, 14.1.
IR (KBr):
2919, 2854, 1721, 1705, 1588, 1490, 1457, 1394 cm-1 Mass (ESI-MS):
712.94[M+Na]+
Compound 9d:
O
O
O
N
NN
CF3
Light yellow solid; mp: 282 oC
1HNMR(400MHz, CDCl3, ): 8.11 (1H, s), 7.90 (2H, d, J = 4 Hz), 7.81 (2H, d, J =
8 Hz), 5.29 (3H, m), 2.51 (1H, m), 2.35 (1H, m), 2.2
5 (2H, d, J = 8), 1.28 (3 H, m), 1.05 (3H, s), 0.99 (3
H, s), 0.94 (3H, s), 0.88 (3H, s), 0.86 (3H, s),
0.84 (3H, s), 0.51 (3H, s).
13C NMR (100 MHz, CDCl3, ): 217.7, 177.6, 144.2, 139.3, 138.0, 127.1, 127.1,
125.5,122.4, 120.3, 55.2, 53.0, 48.2, 47.3, 46.6, 42.1, 39.4, 39.2, 39.1, 38.8, 36.6, 34.1,  26.5,
23.4, 23.3, 21.4, 21.1, 17.0, 16.7, 15.0.
IR (KBr): 2926, 2862, 1731, 1701, 1610, 1512, 1455, 1389 cm-1
Mass (ESI-MS): 701.94[M+Na]+
Compound 9e:
O
O
O
N
NN Cl
White gummy liquid :
1HNMR (400MHz, CDCl3, ): 8.01
(1H, s), 7.68 (2H, d, J = 4 Hz), 7.51 (2H, d, J = 4 Hz), 5.24
(3H, m), 2.61 (1H, m), 2.42 (2H, m), 2.12 (2H, m), 1.90 (3H, m), 1.3 (3H, s), 1.15 (6H, s), 1.
05 (3H, s), 0.90 (3H, s), 0.85 (3H, s), 0.52 (3H, s).
13 C NMR (100 MHz, CDCl3, ): 217.8, 177.6, 144.0, 138.0, 135.4, 134.7, 129.9,
125.5, 122.4, 121.6, 57.1, 55.2, 52.9, 48.2, 47.4, 46.7, 42.1, 39.4, 39.3, 39.1, 38.8, 36.6,
34.1, 32.4, 26.5, 24.1, 23.4, 23.3, 21.4, 21.1,19.5, 17.0, 16.7, 15.1.
IR (KBr): 2924, 2853, 1716, 1701, 1604, 1496, 1446, 1392
cm-1
Mass (ESI-MS): 668.52[M+Na]+
Compound 9f:
O
O
O
N
NN
F
White solid, mp: 279oC
1HNMR (400MHz, CDCl3, ): 8.12 (1H, s), 7.98 (1H, t, J = 8 Hz), 7.46 (1H, m), 7.
32 (2H, m), 5.27 (3H, m), 2.51 (1H, m), 2.37 (1H, m),  2.26 (1H, d, J = 8 Hz), 2.01 (2H, m),
1.86 (3H, m), 1.70 (4H, m), 1.62 (3H,
s), 1.30 (3H, s), 1.08 (3H, s), 1.02 (3H, s), 0.94 (3H, s), 0.86 (3H, s), 0.58 (3H, s).
13 C NMR (100 MHz, CDCl3, ): 217.9, 177.4, 143.5, 138.1, 130.3, 130.2, 125.5,
125.3, 125.2, 124.8, 117.2, 117.0, 57.2, 55.1, 52.9, 48.2, 47.3, 46.7, 42.1, 39.4, 39.3, 39.1,
38.8, 36.6, 34.1, 32.5, 29.7, 26.6, 24.1, 23.4, 21.4, 21.1, 19.5, 17.0, 16.7, 15.1.
IR (KBr): 2926, 2859, 1716, 1695, 1586, 1522, 1481, 1390,
1342, 1309
cm-1
Mass (ESI-MS): 652.12 [M+Na]+
Compound 9g:
O
O
O
N
NN
I
Yellow paste like:
1HNMR (400MHz, CDCl3, ): 8.01 (1H, d, J = 4 Hz), 7.91 (1H, s), 7.51 (1H, t, J
= 12 Hz), 7.45 (1H, d, J = 4 Hz), 7.26 (1H, m), 5.26 (3H, m), 2.51 (1H, m), 2.38 (1H, m), 2.
26 (1H, d, J = 8 Hz), 2.01 (2H, m), 1.90 (3H, m), 1.70 (4H, m), 1.28 (3H, s), 1.12 (3H, s), 1.0
5 (3H, s), 1.02 (3H, s), 0.95 (3H, s), 0.86 (3H, s), 0.74 (3H, s).
13 C NMR (100 MHz, CDCl3, ): 217.8, 177.4, 143.0, 140.4, 139.9, 138.2, 131.5,
129.2, 127.8, 125.9, 125.4, 93.6, 57.3, 55.2, 52.9, 48.2, 47.4, 46.7, 42.2, 39.5, 39.3, 39.1, 38.8,
36.7, 36.6,  34.1, 32.5, 30.6, 29.7, 28.0, 26.6, 24.1, 23.5, 23.4, 21.5, 21.1, 19.6, 17.1, 17.0,
15.3.
IR (KBr): 2929, 2842, 1711, 1698, 1581, 1529,
1462, 1404, 1379, 1322 cm-1
Mass (ESI-MS): 759.94 [M+Na]+
Compound 9h:
O
O
O
N
NN
F3C
Grey white solid, mp: 283 oC
1HNMR(400MHz, CDCl3, ): 7.88 (1H, s), 7.87 (1H, s), 7.72 (2H, m), 7.56 (1H, m)
, 5.26 (3H, m), 4.09 (1H, d, J = 4 Hz), 2.52 (1H, m), 2.37 (1H, m), 2.26 (1H, d, J = 12 Hz),
2.01 (2H, m), 1.90 (3H, m), 1.57 (3H,
s), 1.28 (3H, s), 1.10 (3H, s), 1.05 (3H, s), 1.01 (3H, s), 0.95 (3H,s), 0.87 (3H, s), 0.74 (3H, s).
13C NMR (100 MHz, CDCl3, ):      217.5, 177.4, 143.2, 138.2, 133.0, 130.5, 128.9, 127.4,
126.5, 125.4, 57.2, 52.9, 48.2, 46.7, 42.2, 39.5, 39.3, 39.1, 38.8, 36.7, 36.5,  34.2, 32.5, 30.6,
29.7, 28.0, 26.6, 24.1, 23.4, 21.5,  21.1, 19.6, 17.0, 15.2;
IR (KBr): 2926, 2854, 1728, 1701, 1611, 1512, 1456, 1389 cm-1
Mass (ESI-MS): 701.94[M+Na]+
Compound 9i:
OO
O
N
NN
Br
Grey white solid, mp :280 oC
1HNMR (400MHz, CDCl3, ): 8.01 (1H, s), 7.92 (1H, s),7.68 (1H, d, J = 8 Hz), 7.5
8 (1H, m, J = 8 Hz), 7.42 (1H, t, J = 12 Hz), 5.27 (3H, m), 2.69 (1H, m),
2.40 (1H, m), 2.28 (1H, d, J = 12 Hz), 2.16 (3H, m), 2.01 (2H, m), 1.69 (3H, m), 1.25 (3H, s),
1.05 (3H, s), 0.99 (3H, s), 0.87 (3H,s), 1.01 (3H, s), 0.95 (3H, s), 0.87 (3H, s).
13C NMR (100 MHz, CDCl3, ): 217.8, 177.6, 144.0, 138.0, 137.8, 131.8, 131.1,
130.9, 128.8, 125.5, 123.6, 123.3, 122.6, 118.9, 71.8, 55.1, 53.0, 48.2, 47.3, 46.6, 42.1, 39.4,
39.1, 38.8, 36.6, 34.1, 30.9, 29.7, 26.6, 23.3, 21.4,  21.1, 17.0, 16.7, 15.1;
IR (KBr): 2922, 2851, 1728, 1705, 1592, 1493, 1456 cm-1
Mass (ESI-MS): 712.94 [M+Na]+
Compound 9j:
O
O
O
N
NN
F
White paste:
1HNMR (400MHz, CDCl3, ): 8.09 (1H, s), 7.90 (2H, d, J = 8
Hz), 7.80 (2H, d, J = 8 Hz), 5.27(3H, m), 2.50 (1H, m), 2.36 (1H, m), 2.25 (1H, d, J = 11.2 H
z), 2.16 (1H, s), 1.77 (2H, m), 1.25 (3H, s), 1.06 (3H, s), 1.01 (3H, s), 0.93 (3H, s), 0.87 (3H,
s), 0.85 (3H, s), 0.54 (3H, s).
13C NMR (100MHz, CDCl3, ): 217.9, 177.6, 144.2, 139.3, 138.1, 138.0, 131.0, 130.7
, 127.1, 127.1, 127.1, 125.5, 125.2, 124.8, 124.5, 122.4, 120.3, 57.0, 55.2, 53.0, 48.2, 46.6, 42.
1, 39.4, 39.1, 38.8, 36.6, 36.6, 34.1, 29.7, 26.5, 24.1, 23.4, 23.3, 21.4, 21.1, 17.0, 16.8, 15.0;
IR (KBr): 2928, 2850, 1713, 1705, 1622, 1539, 1435,
1382, 1345, 1310
cm-1
Mass (ESI-MS): 652.12 [M+Na]+
Compound 9k:
O
O
O
N
NN
I
Yellow paste like :
1H NMR (400MHz, CDCl3, ): 8.01(1H, s), 7.68 (2H, d, J = 8.8 Hz), 7.50 (2H, d, J
= 8.8 Hz), 7.45 (1H, d, J = 4 Hz), 7.26 (1H, m), 5.26 (3H, m), 2.37 (1H, m), 2.25 (1H, m), 2.
23 (1H, d, J = 8 Hz), 2.16 (2H, t, J = 4.2 Hz), 1.89 (2H, m), 1.85 (3H, m), 1.26 (3H, s), 1.06 (
3H, s), 1.01 (3H, s), 0.93 (3H, s), 0.88 (3H, s), 0.84 (3H, s), 0.53 (3H, s).
13C NMR (100 MHz, CDCl3, ): 217.6, 177.6, 144.0, 138.1, 135.4, 134.7, 129.9, 125.5,
122.3, 121.6, 57.1, 55.2, 53.4, 53.0, 48.2, 47.4, 46.7, 42.2, 39.5, 39.3, 39.1, 38.8, 36.6, 34.1,
32.5, 31.9, 30.9, 30.6, 29.7, 29.4, 28.0,  26.6, 24.2, 23.4, 23.3,  22.7;
IR (KBr): 2922, 2850, 1705, 1504, 1459, 1375, 1329cm-1
Mass (ESI-MS): 759.96[M+Na]+
Compound 9l:
O
O
O
N
NN CN
Yellowish White solid, mp :284 oC
1H NMR (400MHz, CDCl3, ): 8.04 (1H, s), 7.75 (2H, d, J = 4.2 Hz),7.48 (2H, d, J =
4 Hz), 5.26 (3H, m), 3.66 (2H, s), 2.47 (2H, m), 2.26 (2H, m), 1.97 (3H, m), 1.40
(3H, s), 1.21 (3H, s), 1.05 (3H, s), 0.90 (3H, s), 0.85 (3H, s), 0.52 (3H, s).
13C NMR (100 MHz, CDCl3, ): 217.6, 177.5, 144.1, 138.3, 135.7, 135.0, 129.7,
124.4, 122.9, 122.2, 57.3, 54.2, 52.5, 48.7, 46.1, 45.7, 43.7, 41.3, 38.7, 38.1, 38.0, 36.8, 35.3,
33.6, 29.7, 26.4, 24.6, 23.8, 22.5, 21.6, 20.9, 17.8, 16.2, 15.8.
IR (KBr): 2926, 2848, 1709, 1697,1517, 1462,1424, 1386, 1324
cm-1
Mass (ESI-MS): 673.44[M+Na]+
3.5. Anticancer activity:
3.5.1. Human Cancer cell lines and culture:
The optimum density of seeded cell suspension was introduced to each well of
96-well plates (Iwaki) and exposed to a range of isolated and modified
constituent concentrations. Cells were cultured in (Indian Institute of Integrative
Medicine, CSIR, Jammu, India) humidified atmosphere at 37 oC in 5% CO2. In
the cultured RPMI-1640 medium, known cytotoxic agents, Paclitaxel and
Mitomycin-C (Sigma–Aldrich, Madrid, Spain) were used as positive controls.
The cells were incubated with sample for 48 hours and fixed in cold ice TCA for
1 h at 4 oC. Plates were washed with distilled water and allowed to dry in the air.
Sulpharhodamine-B (SRB) solution (0.4%) was added to each well of 96-well
plates and allowed to stain at room temperature for 30-min. The unbound SRB
solution was removed by washing the plates quickly with 1% (v/v) acetic acid.
The bound SRB dye was solubilised by adding 100 µl of 10 mM unbuffered Tris
base (PH = 10.5) to each well and shaken for 5 min on shaker platform. The
plates were read in a 96-well plate reader at 540 nm.
3.5.2. Cytotoxicity assay:
Sulpharhodamine-B assay was performed against four human cancer cell lines
namely THP-1 (leukemia), A-549 (lung), HEP-2 (liver) and Caco-2 (colon),
which revealed increase in growth of inhibition during 48 h incubation at all
concentrations of 10, 20, 40, 60, 80 and 100 µg/ml of isolated compounds.
DMSO control was set up separately to cancel out the cell death occurred by
DMSO, which was used as a solvent for dissolving samples homogeneously.
Cytotoxicity is expressed as concentration of drug inhibiting cell growth by 50%
(IC50). The results showed that the inhibition of different human cancer cell lines
of varying tissue origin with 10, 20, 40, 60, 80 and 100 µg/ml of sample
concentration imparted significant cellular cytotoxic effects on all the cell lines
particularly on leukemia and colon cancer cells.
In case of synthetically modified compounds, all were assayed for in
vitrocytotoxic potential against cancer cell lines including A-549 (lung), MCF-
7(breast), HCT- 116 (colon), THP-1 (leukemia) and a normal human epithelial
cell line Fr-2 using same protocol and standards. All these compounds were
initially screened at 50 µmol concentration to get the percentage of cell growth
inhibition and compounds which showed significant cytotoxic activity were
further evaluated at different concentrations of 30, 10 and 5µmol concentration to
get the IC50 values.
3.6. Determination of antimicrobial activity:
3.6.1. Microbial Strains and culture media:
The antibacterial activity of isolated and synthetically modified constituents was
tested against a panel of seven bacterialand two fungal strains which were
obtained from Microbial Type Culture Collection (MTCC), Institute of Microbial
Technology (IMTECH) Chandigarh, India. The bacterial and fungal strains used
were Bacillus subtilis MTCC-441, Staphylococcus epidermidis MTCC-435,
Pseudomonas aeruginosa MTCC-1688, Staphylococcus aureus MTCC-96, Salm
onella typhi MTCC-531, Shigella dyssenteriae MTCC-369, Klebsiella pneumoni
a MTCC-19, Penicillium chrysogenum MTCC-947 and Aspergillus nigerMTCC-
1344. Bacterial strains were grown on nutrient agar plates at 37 oC and
maintained on nutrient agar slants, while as the fungal strains were grown on
potato dextrose agar (PDA) plates at 25 oC and maintained on PDA slants. Cell
suspension of microorganisms in NaCl 0.9% was adjusted at 0.5 McFarland to
obtain approximately 106 cfu/ml.
3.6.2. Antimicrobial activity:
The antibacterial and antifungal susceptibility tests were carried out using the
agar well diffusion assay with some modification. The overnight cultures of the
indicator strains of bacteria and 72 hour cultures of fungi were added to 20 ml of
liquid nutrient agar and potato dextrose agar (PDA), respectively.  The contents
of the tubes were transferred to petri plates. After 10 minutes of solidification of
the agar petri plates at room temperature, the punched wells on the plates were
filled with 20 µl of 5 molar solution of each constituent in DMSO and pure
DMSO was used as control. The incubation was carried out for 24 h at 37oC for
bacteria and 72 h at 28 oC for fungi. After the incubation period, the antimicrobial
activity was evaluated by measuring the width of the zones of inhibition.
Ampicillin and Vancomycin (10µg/disc) were used as standards for bacteria,
while as fluconazole (10µg/disc) was used as standard antifungal drug.
3.6.3. Determination of minimal inhibitory concentration (MIC) and
minimum bactericidal concentration (MBC)/minimum fungicidal
concentration (MFC):
The MIC/MFC of constituents was determined by microdilution method,
recommended by National Committee for Clinical Laboratory Standards
(NCCLS) as described previously (Ashour et al., 2009).  The isolates were
dissolved in dimethyl sulphoxide (2.56 mg/ml) and added to the medium, and
then diluted two fold to obtain concentrations in the range of 0.125-512 µg/ml
(0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 and 512  µg/ml). Inoculum
suspension with a final concentration of 0.5x106 cfu/ml was added to a 96-well
micro plate. The MIC was defined as the lowest concentration of compound at
which the microorganism does not demonstrate any visible growth after
incubation at 37 oC for 24 h. The MBC/MFC was defined as the lowest
concentration of constituents at which incubated microorganisms were
completely killed.
3.7. Statistical analysis:
Each experiment was done in triplicate, and mean values were calculated. The
data were recorded as respective means ± standard deviations.
